The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).
Paul Hamberg
No relevant relationships to disclose
Marye Boers-Sonderen
No relevant relationships to disclose
Walter J. Loos
No relevant relationships to disclose
Maja J. De Jonge
No relevant relationships to disclose
Winette T.A. Van Der Graaf
No relevant relationships to disclose
Ben B Suttle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ferry Eskens
No relevant relationships to disclose
Jaap Verweij
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Carla Van Herpen
No relevant relationships to disclose
Stefan Sleijfer
Research Funding - GlaxoSmithKline